Skip to main content

3 Result(s)

within Max Heiduk Remove this filter

and

  1. Article

    Open Access

    Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer

    Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for...

    David Digomann, Max Heiduk, Charlotte Reiche, Jessica Glück… in npj Precision Oncology (2023)

    Download PDF (2282 KB) View Article

  2. Article

    Open Access

    Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma

    The immunosuppressive tumor microenvironment promotes progression of pancreatic ductal adenocarcinoma (PDAC). γδ T cells infiltrate the pancreatic tumor stroma and support tumorigenesis through αβ T cell inhib...

    Adrian M. Seifert, Julian List, Max Heiduk… in Journal of Cancer Research and Clinical On… (2020)

    Download PDF (1350 KB) View Article

  3. Article

    Open Access

    Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels

    Pancreatic ductal adenocarcinoma (PDAC) responds poorly to checkpoint blockade, such as anti-CTLA-4 and anti-PD-1. Galectin-9, a β-galactoside-binding lectin, promotes immune suppression through T-cell inhibit...

    Adrian M. Seifert, Charlotte Reiche, Max Heiduk, Anna Tannert… in Oncogene (2020)

    Download PDF (3168 KB) View Article